Clinical-stage biopharmaceutical company Adocia (Euronext Paris:ADOC) announced on Tuesday that it has filed patent applications for stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone platform.
These combinations, such as CagriSema (cagrilintide and semaglutide), can be administered using standard injection devices, offering convenience and flexibility for patients.
Adocia's innovation addresses the challenge of combining different hormones for more effective obesity treatments. By overcoming compatibility issues, Adocia's BioChaperone platform enables the production of stable formulations that can be administered using existing injection devices. This could significantly improve the accessibility and convenience of these treatments.
Adocia is also researching new peptide combinations for obesity treatment and exploring partnerships to advance these innovations.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition